About

THE AURON TEAM

A CULTURE OF INNOVATION

Auron was founded by a world class team of physicians and scientists with proven expertise in bringing effective differentiation therapies to patients. Their initial successes highlighted the untapped potential of this transformative approach. Expanding on this knowledge, Auron has built a multi-omic computational platform that has enabled a unique understanding of the dysregulated differentiation pathways in cancer cells and has identified novel drug targets applicable across multiple tumor indications.

David Millan, PhD

Chief Scientific Officer

“Every day I’m inspired by the energy and motivation of our team as we pioneer a new approach to transformative medicines. Our vision is to change the treatment paradigm for a wide range of cancer types for which there are no effective treatment options, and ultimately transform the lives of patients and their families.”

Meet the team

Leadership

Leadership

Kate Yen, PhD

Founder & CEO

David Millan, PhD

Chief Scientific Officer

Thomas Graeber, PhD

Chief Data Officer

Andrea Armstrong

Chief People Officer

Auron Team

Laura Antipov, PhD

Senior Director, Head of R&D Strategy and Operations

Andrea Armstrong

Chief People Officer

Betty Chan, PhD

Director, Biochemistry & Biophysics

Joe DeBartolo, PhD

Director, Computational Biology

Thomas Graeber, PhD

Chief Data Officer

Andrew McRiner, PhD

VP, Head of Drug Discovery

David Millan, PhD

Chief Scientific Officer

James Neef

Director, Medicinal Chemistry

Peter Slivka, PhD

Director, Translational Biology

Kimberly Straley
Kimberly Straley

Director, Translational Biology

Henry Wilson
Henry Wilson, PhD

Principal Scientist, Computational Biology

Kate Yen, PhD

Founder & CEO

Founders

Ross Levine, MD

Memorial Sloan Kettering Cancer Center

Eytan Stein, MD

Memorial Sloan Kettering Cancer Center

Matthew Vander Heiden, MD, PhD

Massachusetts Institute of Technology

Kate Yen, PhD

Founder & CEO

Board of Directors

Alexandra Cantley
Alexandra Cantley, PhD

Polaris Partners

Anna French
Anna French, PhD

Qiming Venture Partners USA

Rami Hannoush
Rami Hannoush, PhD

Mubadala Capital

Board Observer

Alon Lazarus, PhD

Arkin Bio Ventures

Marianne Mertens
Marianne Mertens, PhD

Apollo Health Ventures

Board Observer

Briggs Morrison, MD

Independent Chairman of the Board

Brad Robling

Eli Lilly and Company

Board Observer

Kate Yen, PhD

Founder & CEO

Scientific Advisory Board

Stéphane de Botton, MD, PhD

Gustave Roussy Cancer Center

Richard Chesworth, PhD

Former CSO, Kymera Therapeutics

Thomas Graeber, PhD

University of California, Los Angeles

Ross Levine, MD

Memorial Sloan Kettering Cancer Center

Shin-San Michael Su, PhD

Volastra Therapeutics, Inc.

Mikhail (Misha) Roshal, MD, PhD

Memorial Sloan Kettering Cancer Center

Kimberly Stegmaier, MD

Harvard Medical School and Dana-Farber Cancer Institute

Eytan Stein, MD

Memorial Sloan Kettering Cancer Center

George Thomas, MD

Oregon Health & Science University

Matthew Vander Heiden, MD, PhD

Massachusetts Institute of Technology

Investors

These are some of the companies who support our mission:
Apollo Health Ventures
DCVC
Mubadala Capital